Solid tumor resisting release agent including nimustine and the intensifier
A solid tumor and slow-release agent technology, applied in the field of anti-solid tumor sustained-release agents, can solve problems such as unclear effects, achieve the effects of convenient drug injection, increase sensitivity, and reduce costs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0147]Put 90 mg of polylactic acid (PLA) with a molecular weight of 20,000-40,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 10 mg of nimustine, shake well, and then vacuum dry to remove the organic solvent . Shake again and dry in vacuo to remove the organic solvent. Freezing and pulverizing the dried drug-containing solid composition to make a micropowder containing 10% by weight of nimustine, and then suspending in physiological saline containing 1.5% sodium carboxymethylcellulose to obtain the corresponding suspension type Sustained-release injection with a viscosity of 360cp-480cp (at 25°C-30°C). The subcutaneous release time is 25-30 days.
Embodiment 2
[0149] Put 75 mg of polylactic acid (PLA) with a molecular weight of 30,000-50,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 25 mg of nimustine, re-shake, and then vacuum dry to remove the organic solvent . The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant containing 25% by weight of nimustine for treating solid tumors. The subcutaneous release time is 35-40 days.
Embodiment 3
[0151] Put 95 mg of polylactic acid (PLA) with a molecular weight of 15,000-30,000 as a pharmaceutical excipient into a container, add an organic solvent of 100 ml of dichloromethane to dissolve and mix, add 5 mg of nimustine, re-shake, and then vacuum dry to remove the organic solvent . The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant containing 5% by weight of nimustine for treating solid tumors. The subcutaneous release time is 30-40 days.
PUM
Property | Measurement | Unit |
---|---|---|
glass transition temperature | aaaaa | aaaaa |
melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com